EGFR, as one of the most common targets for cancer therapy, is reported to be overexpressed on the surface of a wide variety of cancer cells.[20] The Fab’ fragment of Erbitux, a clinically applied antibody of EGFR, was conjugated to the nanophotosensitizers as the targeting moiety. This evidence concerns the gene EGFR and cancer.